BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21057568)

  • 1. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma.
    Aboziada MA; Hamza HM; Abdlrahem AM
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):167-74. PubMed ID: 21057568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
    Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
    Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
    Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
    J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative concurrent chemoradiotherapy against muscle-invasive bladder cancer: results of partial cystectomy in elderly or high-risk patients.
    Kageyama Y; Okada Y; Arai G; Hyochi N; Suzuki M; Masuda H; Hayashi T; Kawakami S; Okuno T; Ishizaka K; Kihara K
    Jpn J Clin Oncol; 2000 Dec; 30(12):553-6. PubMed ID: 11210165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
    Khosravi-Shahi P; Cabezón-Gutiérrez L
    Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.